Baillie Gifford & Co
STOK icon

Baillie Gifford & Co’s Stoke Therapeutics STOK Stock Holding History

Baillie Gifford & Co’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.9M Sell
517,275
-57,907
-10% -$1.86M 0.02% 187
2026
Q1 		$18.7M Buy
575,182
+328,282
+133% +$10.8M 0.02% 185
2025
Q4 		$7.84M Buy
+246,900
New +$7.42M 0.01% 224

Other funds holding STOK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Baillie Gifford & Co's STOK Position: Q2 2026 in Review

Baillie Gifford & Co reduced its Stoke Therapeutics (STOK) stake by 10% in Q2 2026, selling an estimated $1.86M and leaving 517,275 shares worth $16.9M. The position accounts for 0.02% of the portfolio, ranked #187.

Baillie Gifford & Co first reported a position in STOK in Q4 2025 and has held it in 3 quarters since. The position peaked at $18.7M in Q1 2026. 197 funds tracked by Wall St. Rank hold STOK as of Q2 2026.

  • Baillie Gifford & Co held 517,275 shares of Stoke Therapeutics worth $16.9M as of Q2 2026.
  • Baillie Gifford & Co sold 57,907 Stoke Therapeutics shares in Q2 2026, an estimated $1.86M.
  • Stoke Therapeutics made up 0.02% of Baillie Gifford & Co's portfolio in Q2 2026, its #187 holding.
  • Baillie Gifford & Co first reported a position in Stoke Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Baillie Gifford & Co's Stoke Therapeutics position peaked at $18.7M in Q1 2026.
  • 197 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q2 2026.

Based on Baillie Gifford & Co's 13F filing for Q2 2026, filed 6 Aug 2026.